Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TPFI): A possible mechanism for difference in therapeutic efficacy

Thrombosis Research

Volumn 91, Issue 4, 1998, Pages 177-181

  Hansen, John Bjarne ^a   Sandset, Per Morten ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antithrombin; Heparin; Low molecular weight heparin (LMWH); Protein C; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0032528864     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00079-6     Document Type: Article

References (14)

1. Noble S., Peters D.H., Goa K.L. Enoxaparin - a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs. 49:1995;388-410.
2. Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Results of a meta-analysis Am J Med. 100:1996;269-277.
3. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A.A., Premmereur J., Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337;447-52:1997.
4. Bourin M.C., Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 289:1993;313-330.
5. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50:1988;803-813.
6. Broze G.J. Jr., Warren L.A., Novotny W.F., Higuchi D.A., Girard J.J., Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa. Insight into its possible mechanism of action Blood. 71:1988;335-343.
7. Marciniak E., Gockerman J.P. Heparin-induced decrease in circulating antithrombin-III. Lancet. 2:1977;581-584.
8. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemostas. 76:1996;703-709.
9. Bratt G., Törnebohm E., Granqvist S., Åberg W., Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas. 54:1985;813-817.
10. Østergaard P.B., Beck T.C., Ørsted H., Svendsen A., Nordfang O., Sandset P.M., Hansen J.B. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res. 87:1997;447-459.
11. Institute Inc S.A.S. SAS/STAT Guide for Personal Computers, Version 6. 1987;SAS Institute, Cary, NC.
12. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., Mannucci P.M., Rosenberg R.D. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 90:1994;61-68.
13. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med. 327:1992;141-145.
14. Wilson C, Baird S, Trouton T. Enoxaparin versus unfractionated heparin after thrombolysis for acute myocardial infarction. (Abstract). Presented at the satellite symposium: Discovery - the emerging role of low molecular weight heparins in acute coronary syndromes. 70th Scientific Sessions of the American Heart Association, Orlando, FL: November 1997.